Literature DB >> 24325965

Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans.

Weimin Zhong1, Carrie Reed, Patrick J Blair, Jacqueline M Katz, Kathy Hancock.   

Abstract

Natural infection-induced humoral immunity to matrix protein 2 (M2) of influenza A viruses in humans is not fully understood. Evidence suggests that anti-M2 antibody responses following influenza A virus infection are weak and/or transient. We show that the seroprevalence of anti-M2 antibodies increased with age in 317 serum samples from healthy individuals in the United States in 2007-2008. Infection with 2009 pandemic H1N1 influenza A virus (A[H1N1]pdm09) elicited a recall serum antibody response to M2 protein of A(H1N1)pdm09 in 47% of the affected 118 individuals tested. Anti-M2 antibody responses were more robust among individuals with preexisting antibodies to M2 protein. Moreover, the antibodies induced as a result of infection with A(H1N1)pdm09 were cross-reactive with M2 protein of seasonal influenza A viruses. These results emphasize the need to further investigate the possible roles of anti-M2 antibodies in human influenza A virus infection.

Entities:  

Keywords:  Antibody; Human; Influenza A virus; Matrix protein 2

Mesh:

Substances:

Year:  2013        PMID: 24325965     DOI: 10.1093/infdis/jit811

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Authors:  Silvie Van den Hoecke; Katrin Ehrhardt; Annasaheb Kolpe; Karim El Bakkouri; Lei Deng; Hendrik Grootaert; Steve Schoonooghe; Anouk Smet; Mostafa Bentahir; Kenny Roose; Michael Schotsaert; Bert Schepens; Nico Callewaert; Falk Nimmerjahn; Peter Staeheli; Hartmut Hengel; Xavier Saelens
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

2.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

3.  Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.

Authors:  Lei Deng; Jong R Kim; Timothy Z Chang; Han Zhang; Teena Mohan; Julie A Champion; Bao-Zhong Wang
Journal:  Virology       Date:  2017-06-13       Impact factor: 3.616

4.  Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein.

Authors:  Sinthujan Jegaskanda; Mary Dawn T Co; John Cruz; Kanta Subbarao; Francis A Ennis; Masanori Terajima
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

5.  High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.

Authors:  Masanori Terajima; Mary Dawn T Co; John Cruz; Francis A Ennis
Journal:  J Infect Dis       Date:  2015-03-20       Impact factor: 5.226

6.  Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody.

Authors:  Ki Joon Cho; Bert Schepens; Jong Hyeon Seok; Sella Kim; Kenny Roose; Ji-Hye Lee; Rodrigo Gallardo; Evelien Van Hamme; Joost Schymkowitz; Frederic Rousseau; Walter Fiers; Xavier Saelens; Kyung Hyun Kim
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

7.  Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Authors:  Yao Ma; Ye Wang; Chunhong Dong; Gilbert X Gonzalez; Yufeng Song; Wandi Zhu; Joo Kim; Lai Wei; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2021-11-04       Impact factor: 5.307

Review 8.  Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Authors:  Suzanne L Epstein
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

Review 9.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

10.  Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.

Authors:  Jiwon Jung; Sophia T Mundle; Irina V Ustyugova; Andrew P Horton; Daniel R Boutz; Svetlana Pougatcheva; Ponraj Prabakaran; Jonathan R McDaniel; Gregory R King; Daechan Park; Maria D Person; Congxi Ye; Bing Tan; Yuri Tanno; Jin Eyun Kim; Nicholas C Curtis; Joshua DiNapoli; Simon Delagrave; Ted M Ross; Gregory C Ippolito; Harry Kleanthous; Jiwon Lee; George Georgiou
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.